Table 1.
Relationship between the presence of JAK-2 mutation and variable of cases with thrombocytosis
|
JAK2 (+)
n: 58 |
JAK 2 (-)
n:78 |
P-value | |
|---|---|---|---|
| Age (Mean±SD) years | 60.7±15.9 | 53.7±14.2 | 0.004 |
| Gender | |||
| Male n (%) Female n (%) |
24 (41.4) 34 (58.6) |
41 (52.6) 37 (47.4) |
0.197 |
| platelet count (x 109 / L) | 952±147 | 792.025±235 | 0.765 |
| Vertical spleen length (Mean±SD) | 130.9±20.6 | 139.8±22.0 | 0.004 |
| Biopsy | |||
| Performed Non-performed |
58 (54.8) 0 90.0) |
48(45.2) 30 (100) |
<0.001 |
| Definite diagnosis | |||
| Essential thrombocytosis Inflammatory Iron deficiency anemia Myeloproliferative neoplasms (MPN) Splenectomy Primary myelofibrosis Policytemia vera Chronic myeloid leukemia Malignancy Myelodysplastic syndrome (MDS) MDS + MPN Autoimmune diseases |
33 (56.9) 0 (0.0) 0 (0.0) 3 (5.2) 0 (0.0) 5 (8.6) 16 (27.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) |
26 (33.3) 18 (23.1) 8 (10.3) 6 (7.7) 5 (6.4) 4 (5.1) 3 (3.8) 3 (3.8) 2 (2.6) 1 (1.3) 1 (1.3) 1 (1.3) |
<0.001 |